Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:AIM OTCMKTS:GLUC NASDAQ:MYNZ NASDAQ:PRTG On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIMAIM ImmunoTech$9.21+1.2%$9.10$0.06▼$14.93$6.96M0.98562,718 shs4,504 shsGLUCGlucose Health$0.10+3.1%$0.09$0.08▼$0.44$1.74M1.875,580 shs4,800 shsMYNZMainz Biomed$1.85+27.6%$1.96$1.34▼$20.08$4.99M0.21139,540 shs418,723 shsPRTGPortage Biotech$5.88-0.8%$7.27$2.10▼$23.01$6.22M0.23992,709 shs10,064 shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIMAIM ImmunoTech+2.82%+1.96%-0.44%-0.44%-75.34%GLUCGlucose Health+5.15%-1.96%+7.76%+10.99%-76.02%MYNZMainz Biomed+3.57%+2.11%-30.12%-56.46%-92.40%PRTGPortage Biotech+5.33%+0.68%-29.49%+18.13%+100.34%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAIMAIM ImmunoTech1.4867 of 5 stars3.50.00.00.02.50.00.0GLUCGlucose HealthN/AN/AN/AN/AN/AN/AN/AN/AMYNZMainz Biomed3.0769 of 5 stars3.35.00.00.00.60.01.3PRTGPortage Biotech0.6593 of 5 stars0.05.00.00.00.61.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAIMAIM ImmunoTech 3.00Buy$275.002,885.88% UpsideGLUCGlucose Health 0.00N/AN/AN/AMYNZMainz Biomed 2.50Moderate Buy$14.00656.76% UpsidePRTGPortage Biotech 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAIMAIM ImmunoTech$146K48.19N/AN/A$0.20 per share46.05GLUCGlucose Health$380K4.72N/AN/AN/A∞MYNZMainz Biomed$890K7.15N/AN/A$2.61 per share0.71PRTGPortage BiotechN/AN/A$8.05 per share0.73$3.74 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAIMAIM ImmunoTech-$28.96M-$24.00N/AN/AN/A-12,594.21%-421.73%-147.54%N/AGLUCGlucose Health-$320K-$0.03N/A∞N/A-82.29%N/AN/AN/AMYNZMainz Biomed-$21.65M-$65.60N/AN/AN/AN/AN/AN/AN/APRTGPortage Biotech-$75.34M-$41.65N/A∞N/AN/AN/AN/A8/26/2025 (Estimated)Compare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAIMAIM ImmunoTechN/AN/AN/AN/AN/AGLUCGlucose HealthN/AN/AN/AN/AN/AMYNZMainz BiomedN/AN/AN/AN/AN/APRTGPortage BiotechN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAIMAIM ImmunoTech0.050.750.75GLUCGlucose HealthN/AN/AN/AMYNZMainz Biomed0.141.321.26PRTGPortage BiotechN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAIMAIM ImmunoTech12.02%GLUCGlucose HealthN/AMYNZMainz BiomedN/APRTGPortage Biotech13.36%Insider OwnershipCompanyInsider OwnershipAIMAIM ImmunoTech0.02%GLUCGlucose HealthN/AMYNZMainz Biomed18.20%PRTGPortage Biotech42.07%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAIMAIM ImmunoTech20764,00068.74 millionNot OptionableGLUCGlucose Health147,00017.41 millionN/ANot OptionableMYNZMainz Biomed303.44 million2.81 millionNot OptionablePRTGPortage Biotech61.05 million608,000OptionableGLUC, MYNZ, PRTG, and AIM HeadlinesRecent News About These CompaniesPortage Biotech Regains Nasdaq Compliance, Maintains Listing On Capital Market | NasdaqJune 27, 2025 | nasdaq.comPRTG Portage Biotech Inc. - Seeking AlphaJune 26, 2025 | seekingalpha.comPortage Biotech Inc. (PRTG) Income Statement - Yahoo FinanceJune 26, 2025 | finance.yahoo.comPortage Biotech Regains Nasdaq ComplianceJune 25, 2025 | tipranks.comPortage Biotech Regains Full Compliance with Nasdaq Continued Listing RequirementsJune 25, 2025 | globenewswire.comPortage Biotech Inc. (PRTG) Cash Flow - Yahoo FinanceJune 24, 2025 | finance.yahoo.comPortage Biotech acquires stake in Compedica for $5 millionJune 10, 2025 | investing.comPortage Biotech and Compedica Forge Strategic Alliance with Stock ExchangeJune 9, 2025 | tipranks.comPortage Biotech Inc. Enters Subscription Agreement with Compedica Holdings Limited for Strategic Equity InvestmentJune 9, 2025 | quiverquant.comQPortage Biotech and Compedica Stock-for-Stock ExchangeJune 9, 2025 | globenewswire.comPortage Biotech Shares Rise on Confirmatory Trial Results, Plans for Human TrialApril 28, 2025 | marketwatch.comPortage Biotech stock soars on promising preclinical resultsApril 28, 2025 | za.investing.comPortage Biotech Stock Surges On New Preclinical Data In Mesothelioma Trial: Retail Gets More BullishApril 28, 2025 | msn.comPortage Biotech Inc. Reports Positive Preclinical Efficacy Data for PORT-7 at AACR Annual Meeting 2025April 28, 2025 | quiverquant.comQPortage Biotech Reports Confirmatory Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7April 28, 2025 | globenewswire.comInsider Stock Buying Reaches US$2.15m On Portage BiotechApril 26, 2025 | finance.yahoo.comPortage Biotech Inc. Common Stock (PRTG) Pre-MarketMarch 30, 2025 | nasdaq.comPortage Biotech presents preclinical data for PORT-7March 28, 2025 | markets.businessinsider.comPortage Biotech Shares More Than Double After Results of PORT-7 Tumor Treatment TrialMarch 27, 2025 | marketwatch.comPortage Biotech stock soars on promising preclinical dataMarch 27, 2025 | investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGLUC, MYNZ, PRTG, and AIM Company DescriptionsAIM ImmunoTech NYSE:AIM$9.21 +0.11 (+1.21%) As of 02:27 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente; Jubilant HollisterStier; Sterling Pharma Solutions; Erasmus University Medical Center Rotterdam; Azenova, LLC; and Alcami Corporation. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.Glucose Health OTCMKTS:GLUC$0.10 +0.00 (+3.10%) As of 03:44 PM EasternGlucose Health, Inc. engages in the formulation, manufacturing, marketing, and distribution of soluble fiber infused nutritional beverages. It offers soluble fiber infused powdered iced tea, and flavored drink mixes for pre-diabetic and diabetic persons under the GLUCODOWN brand in North America. The company was formerly known as Bio-Solutions Corp. and changed its name to Glucose Health, Inc. in November 2014. Glucose Health, Inc. was incorporated in 2007 and is based in Bentonville, Arkansas.Mainz Biomed NASDAQ:MYNZ$1.85 +0.40 (+27.59%) Closing price 04:00 PM EasternExtended Trading$1.79 -0.06 (-3.24%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. The company was founded in 2008 and is based in Mainz, Germany.Portage Biotech NASDAQ:PRTG$5.88 -0.05 (-0.84%) Closing price 04:00 PM EasternExtended Trading$5.88 0.00 (-0.09%) As of 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Portage Biotech Inc., a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline includes PORT-2 for treatment of refractory NSCLC, melanoma, and refractory melanoma that is in phase I and phase II clinical trials; PORT-3, for treatment of solid tumors, which is in phase I clinical trials; PORT-6, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ia clinical trials; PORT-7, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ib clinical trials; PORT-1, an intratumoral amphiphilic solutions for treatment of advanced soft tissue sarcoma, which is in phase 3 clinical trials; PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; and PORT-5, a VLP-STING to treat of solid tumors that is in preclinical trials. The company is based in Tortola, British Virgin Islands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tesla Stock Could Accelerate on New EV Tax Legislation SoundHound Rises as Short Sellers Exit and AI Demand Grows Why Marvell Could Be the Smartest AI Bet Under $80 Autodesk Stock Ready to Rip? Q3 May Be the Turning Point Amazon's Prime Day Pullback Meets Bullish Golden Cross Signal Palantir’s Revenue Surge to $1B: Growth vs. Valuation Chime Financial: Analysts Ring In—And It’s a Buy Is Fortinet Ready to Break Out After Months of Consolidation? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
